ArticleRSC advances2026
A benchmark dataset and interpretable deep learning framework for drug-induced developmental neurotoxicity prediction.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developmental neurotoxicity (DNT) represents a critical yet underevaluated toxicity endpoint within current chemical safety assessment frameworks, particularly in the context of drug development. In the present study, we constructed a standardized benchmark dataset comprising 2724 structurally curated compounds, including 1362 DNT-positive chemicals derived from the Developmental Neurotox Reference List (DNTREF) of the U.S. Environmental Protection Agency (EPA) and 1362 property-matched presumed negative compounds (non-neuroactive drug-like compounds) selected from the ChEMBL database. Using this benchmark dataset, we systematically evaluated seven representative quantitative structure activity relationship (QSAR) modeling paradigms, covering traditional machine learning, deep neural networks, molecular language models, and graph neural networks. Across all models, the area under the receiver operating characteristic curve (AUC) values ranged from 0.85 to 0.90 on an independent test set. Among these, a deep neural network based on MACCS fingerprints achieved the highest sensitivity in identifying DNT-positive compounds, supporting its utility in early-stage drug safety screening where minimizing false negatives is critical. Furthermore, SHAP-based interpretability analysis revealed key structural motifs associated with DNT, highlighting the roles of hydrophobic aromatic frameworks, electrophilic reactivity, and polar functional groups in modulating predicted neurodevelopmental risk. Collectively, this study provides a reproducible benchmark dataset and an interpretable QSAR framework that supports early DNT risk prioritization and offers actionable structural insights for medicinal chemistry optimization in drug discovery.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.